Introduction
Chronic idiopathic inflammatory bowel diseases (IBD), which affect 1.0-1.5 million Americans [1 ] , are a heterogeneous group of disorders resulting from continuous enteric microbial antigenic stimulation of pathogenic T cell responses in individuals with genetic defects in mucosal barrier function, innate bacterial killing or immunoregulation [2 ] . Altered microbial composition, defective clearance of bacteria and enhanced mucosal uptake in Crohn's disease and ulcerative colitis increase immune stimulation. Crohn's disease and ulcerative colitis preferentially occur in areas of highest intestinal bacterial concentrations and fecal flow sustains inflammation of Crohn's disease [3] . Ciprofloxacin and metronidazole treat colonic Crohn's disease and experimental colitis in a number of rodent models [4] . This review describes evidence of the roles of commensal bacteria in the pathogenesis of IBD in articles published from January 2007 to December 2008.
Defective bacterial killing in Crohn's disease
Pathophysiologic similarities between Crohn's disease and chronic granulomatous diseases associated with defective phagocyte function, polymorphisms of genes regulating clearance of intracellular pathogens and observed defects in innate antimicrobial function have led to the hypothesis that a subset of Crohn's disease is caused by defective clearance of commensal, opportunistic or pathogenic bacteria with subsequent initiation of compensatory antibacterial effector T cells that cause tissue damage [2 ,5] . Secretion of both a and b-defensins is defective in Crohn's disease [6, 7] , with decreased Paneth cell a-defensin production due to reduced expression of Tcf-4, a WNTsignaling pathway transcription factor [8] . The truncation mutation of NOD2, which is an intracellular receptor for the peptidoglycan component muramyl dipeptide, results in decreased ileal a-defensin production [6] . Furthermore, NOD2-deficient mice exhibit decreased a-defensin defcr-4 [9] , whereas deletion of the autophagy gene ATG16L1 or the endoplasmic reticulum stress protein XBP-1 results in Paneth cell morphologic changes and decreased expression of antimicrobial peptides [10 ,11 ] . Crohn's disease is associated with genetic polymorphisms of at least two autophagy pathway components, ATG16L1 and IRGM, which, like NOD2 and NCF2, regulate intracellular bacterial killing [12 -14 ] . Decreased antimicrobial peptide secretion could lead to overgrowth, increased mucosal adherence and translocation of commensal bacteria, whereas defective clearance of invasive or phagocytosed bacteria promotes persistence of viable intracellular bacteria ( Fig. 1 ). Both mechanisms could result in excessive antigenic stimulation of pathogenic Th1/Th17 cells, chronic granulomatous inflammation and susceptibility to infection by traditional and opportunistic pathogens.
Microbial pathogens
Comprehensive culture and molecular-based analyses of the microbiota of IBD patients fail to identify consistent enrichment of individual pathogenic species in IBD tissues. However, bacterial pathogens continue to reap attention because of similarities between Crohn's disease, ulcerative colitis and enteric infections and the hope of finding a cure analogous to Helicobacter pylori in peptic ulcers.
Mycobacterium avium subspecies paratuberculosis
Mycobacterium avium subspecies paratuberculosis (MAP) causes spontaneous granulomatous enterocolitis (Johne's disease) with diarrhea and wasting in ruminants, making this obligate intracellular pathogen a credible causative agent of Crohn's disease [15] . After considerable investigation, the link between MAP and Crohn's disease remains neither substantiated nor invalidated. Many investigators continue to measure the MAP-specific insertion element IS900 DNA in the tissue and/or blood of IBD patients using polymerase chain reaction (PCR) with mixed results (Table 1) [20] [21] [22] .
One recent blinded study offered an alternative method to PCR for identifying MAP in patients with Crohn's disease [25] . Coded, paraffin-embedded surgical resections from Crohn's disease and control patients at two centers subjected to acid-fast staining and rRNA in-situ hybridization (ISH) for MAP were visualized with oilimmersion microscopy. Both methods provided positive results in 10/17 patients with Crohn's disease [59%, 95% confidence interval (CI) 36-78], contrasted with 5/35 control patients [odds ratio (OR) for Crohn's disease versus controls ¼ 8.6, P ¼ 0.002]. Agreement between the two methods was good, but the time-consuming ISH probes could not discriminate between mycobacterial subspecies.
Defective bacterial killing by innate immune cells could increase risk of infection by intracellular pathogens. Two
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Figure 1 Defective containment of commensal bacteria in IBD
Crohn's disease genes that affect bacterial killing result in defective containment of commensal bacteria. NOD2 polymorphisms result in defective a-defensin production and clearance of intracellular bacteria. Overgrowth of mucosal bacteria occurs with defective secretion of antimicrobial peptides (NOD2 and ATG16L1 polymorphisms) or secretory IgA. Inefficient killing of phagocytosed bacteria (NOD2, ATG16L1, NCF4 and IGRM polymorphisms) results in persistent intracellular bacteria and ineffective clearance of bacterial antigens. Increased mucosal permeability leads to overwhelming exposure of bacterial TLR ligands and antigens that activate pathogenic innate and T cell immune responses. Modified from [2 ] and used with permission of Elsevier Publishing Company. IBD, inflammatory bowel diseases; Il, interleukin; LPS, lipopolysaccharide; TNF, tumor necrosis factor. recent studies showed no association between MAP and NOD2 mutations. No significant association was seen in New Zealand in patients with Crohn's disease for carriage of heterozygous or homozygous NOD2 mutations and MAP status [21] , or between MAP serologies and NOD2 polymorphisms in a large, population-based study in Manitoba [26 ] . A recent epidemiologic study also failed to support exposure to MAP by contaminated milk or water [27 ] . Furthermore, consumption of pasteurized milk and fruit was associated with a reduced risk of Crohn's disease, whereas meat intake was associated with an increased risk. Finally, a well designed, 2-year prospective trial of clarithromycin, rifabutin and ethambutol failed to show sustained clinical response in patients with Crohn's disease [28 ] .
Recent studies possibly linking MAP to pathogenic mechanisms of Crohn's disease fuel the ongoing debate. Two hundred and thirty-five patients with Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS) and no known disease were tested for presence of MAP IS900 DNA and cytokine secretion in intestinal biopsy samples [23] . Greater tumor necrosis factor levels correlated with the presence of MAP in patients with Crohn's disease (P < 0.05). However, there was no correlation of MAP with interleukin (IL)-2, IL-12, IL-10 and interferon (IFN)-g secretion. A separate study linked MAP to active Crohn's disease via IL-4 and IL-2 cytokine profiles in peripheral blood with no differences in IFN-g or tumor necrosis factor levels [24] .
Finally, MAP was recently reported to induce experimental colitis in gnotobiotic IL-10 À/À mice [29] . Germ-free IL-10 À/À mice receiving a single oral dose of milk containing 10 4 colony-forming unit (CFU) of live MAP obtained from a patient with Crohn's disease developed more severe and aggressively progressive colitis, had higher serum amyloid A, IFN-g and tumor necrosis factor levels, and lost more weight than did IL-10 À/À mice that received heat-killed MAP.
Despite continued suggestions of a link between MAP and IBD, it remains doubtful that MAP is the causative agent of most Crohn's disease patients, although infection of a subset of patients with intracellular killing defects caused by ATG16L1, IGRM or NCF4 needs to be investigated. Crohn's disease-related NOD2 polymorphisms do not appear to be risk factors for MAP infection.
Functional changes in Escherichia coli
Darfeuille-Michaud and colleagues [30, 31] [40 ] . TLR4 polymorphisms did not influence monocyte response. In preliminary studies, we showed that macrophages from NOD2-deficient mice display defective clearance of a murine AIEC strain with prolonged secretion of IL-12/23 p40 and tumor necrosis factor [41] . These findings demonstrate the importance of genetically programmed host immune responses to diseaserelated bacteria in the pathogenesis of Crohn's disease.
Enteric pathogens as environmental triggers
A case-control study examining medical records of 3019 US soldiers who developed IBD and 11 646 matched controls compared data using a conditional logistic regression model to determine that a single episode of infectious gastroenteritis increased the risk of IBD (OR 1.40, CI 1.19-1.66) [42] . These results suggest that a selflimited enteric pathogen could trigger IBD, possibly by breaking the mucosal barrier and initiating an early inflammatory response in a genetically susceptible host with immunoregulatory abnormalities [2 ]. Clostridium difficile can reactivate quiescent IBD [43 ] and induce acute experimental epithelial injury by Fas-mediated apoptosis [44] . Likewise enterotoxigenic Bacteroides fragilis can induce experimental colitis and IL-17 production [45] . A role for nonpylori Helicobacter in IBD pathogenesis is unlikely based on detection of species-specific serum antibodies in only 6/137 IBD patients [46] .
Dysbiosis
Recent studies in rodents confirm that bacterial composition changes with colonic inflammation and/or infection [47] . Use of molecular techniques is clarifying changes in the composition of the mucosally associated and fecal microbiota in patients with Crohn's disease and ulcerative colitis and vastly extending previous culture-based studies ( Table 2) .
Examining DNA libraries of mucosal-associated microbiota, which may be more relevant than the fecal microbiota to the pathogenesis of IBD, reveals that patients with Crohn's disease and ulcerative colitis have decreased complexity of commensal bacteria [16 ] . Most notably, members of the phyla Bacteroidetes and Firmicutes are decreased in Crohn's disease and ulcerative colitis. These organisms promote gastrointestinal health in multiple ways [59] . Reduced Faecalibacterium prausnitzii, a major member of the family Firmicutes, in patients with Crohn's disease [16 ,50 ] was confirmed and associated with a higher risk of postresection recurrence of ileal Crohn's disease [49 ] . In-vitro peripheral blood mononuclear cell stimulation by F. prausnitzii decreased IL-12 and IFN-g production and stimulated secretion of IL-10. Oral administration of either live F. prausnitzii or its supernatant reduced the severity of trinitrobenzene sulfonic acid (TNBS) colitis and corrected the associated dysbiosis. In parallel, the abun- Nonpathogenic bacteria can cause colitis in hosts with immunoregulatory and mucosal barrier deficits. When germ-free IL-10 À/À and wild-type mice were inoculated with nonpathogenic E. faecalis and/or E. coli, dual-associated IL-10 À/À (but not wild-type) mice developed aggressive Th1/Th17-mediated colitis within 3 weeks that progressed to severe pancolitis by 7 weeks [60 ] .
A separate study revealed that uptake of nonpathogenic E. coli strains K-12 and HB101 by specialized follicleassociated epithelial cells overlying Peyer's patches (the site of the earliest observable microscopic lesions of recurrent Crohn's disease), is increased in patients with Crohn's disease, but not in patients with ulcerative colitis [61 ] . Increased E. coli localized within dendritic cells of Crohn's disease mucosa correlated with augmented tissue release of tumor necrosis factor.
Metabolic products of the microbiota have important effects on mucosal epithelial cell and immune function [2 ] . Butyrate and other short-chain fatty acids are the primary metabolic substrates of colonocytes, with rectal epithelial cells dependent on this fuel source, whereas hydrogen sulfide, nitric oxide and serine proteases produced by a subset of commensal microbiota can injure epithelial cells and matrix components [62 ]. Hydrogen sulfide and nitric oxide block butyrate metabolism and could lead to a state of epithelial starvation relevant to the pathogenesis of ulcerative colitis.
Probiotics
Animal models and human studies suggest that therapeutically manipulating the balance between beneficial and detrimental intestinal bacterial species can influence health and disease [63] . Use of probiotics (viable, nonpathogenic microorganisms that exert health benefits beyond basic nutrition), to shift this balance to favor protective species and treat IBD, has been extensively reviewed [63,64 ,65,66,67 ] , yet the role for probiotics in treating Crohn's disease and ulcerative colitis remains undetermined because most trials are underpowered and therefore not definitive.
In a TNBS colitis model, oral Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus casei reduced intestinal inflammation [68] . L. casei had more modest protection than the other probiotic species, yet in a separate in-vitro study, live L. casei decreased tumor necrosis factor, IFN-g, IL-2, IL-6, IL-8 and CXCL1 secretion by explanted Crohn's disease mucosa and counteracted the proinflammatory effects of commensal E. coli ATCC 35345 [69] . This and other studies emphasize hostspecific responses to probiotics. Other probiotic species control aberrant immune responses in intestinal tissue. Bifidobacterium bifidum (BGN4) prevented colitis in a murine CD4 þ CD45RB high T cell transfer model [70 ] . Lactobacillus gasseri expressing manganese superoxide dismutase ameliorated colitis in IL-10 À/À mice, demonstrating the therapeutic potential of recombinant bacteria engineered to secrete biologically active molecules [71 ] .
Orally administered Lactobacillus suntoryeus HY7801 ameliorated TNBS-induced colitis, decreased colonic IL-1b, IL-6 and tumor necrosis factor expression and inhibited TLR4-linked NFkB activation [72 ] . Bifidobacteriafermented milk enhanced IL-10 production in peripheral blood mononuclear cells from patients with ulcerative colitis and inhibited IL-8 secretion by intestinal epithelial cells [73] . Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 fed in yogurt to IBD patients had peripheral blood anti-inflammatory effects. In an in-vitro study, L. reuteri potently suppressed human tumor necrosis factor production by lipopolysaccharide-activated monocytes and monocyte-derived macrophages from children with Crohn's disease in a strain-dependent manner by inhibiting activation of mitogen activated protein kinaseregulated c-Jun and the transcription factor AP-1 [74 ] .
Several groups have investigated the probiotic combination VSL#3 as a treatment for IBD based on its ability to maintain remission in relapsing pouchitis [75, 76] . This combination of four live Lactobacillus strains (L. casei, L. bulgaricus, L. plantarium and L. acidophilus), three live Bifidobacterium strains (B. longum, B. breve and B. infantis), and one live Streptococcus strain (S. thermophilus), dosedependently ameliorated DSS-induced colitis in weanling rats [77] . In a small (N ¼ 18) open-label study, VSL#3 induced remission in 56% of pediatric patients with mild to moderate ulcerative colitis. Six percentage showed a response, and 39% had no response or did worse with treatment [78 ] . Daily oral VSL#3 significantly reduced the pouchitis disease activity index and expanded the number of mucosal regulatory T cells following colectomy with ileal pouch anal anastomosis [79 ] . Two components of VSL#3, B. longum and B. breve, in combination with the prebiotic psyllium, were well tolerated at high doses and induced remission in 6/10 patients with Crohn's disease who had failed a regimen of aminosalicylates and prednisolone [80 ] .
Similar to Sokol et al.'s [49 ] studies with F. prausnitzii, an Israeli group isolated and characterized a new putative protective bacterial species, Enterococcus durans, from the fecal microbiota of a healthy human vegetarian [81 ] . In a DSS model of colitis, oral administration of E. durans significantly ameliorated colitis compared to controls and mice fed Lactobacillus delbrueckii. To properly note negative studies, oral administration of Lactobacillus johnsonii failed to prevent early postoperative endoscopic recurrence of Crohn's disease 12 weeks after ileo-cecal resection [82] .
To date, probiotics appear to be more effective in preventing relapse of ulcerative colitis and pouchitis, with poor results in Crohn's disease. Examining F. prausnitzii in preventing postoperative recurrence of Crohn's disease will be quite interesting and could lay the foundation for targeted correction of dysbiotic microbiota in IBD. Use of prebiotics, which are poorly absorbed oligosaccharides that stimulate growth and metabolic activity of beneficial microbiota, could be a low-cost, nontoxic strategy to correct dysbiosis in IBD patients.
Conclusion and future directions
There remains no evidence that MAP is a causative agent in the pathogenesis of IBD. A more likely scenario involves specific E. coli strains and other species with virulence factors that allow them to adhere to and invade epithelial cells and persist within macrophages. These strains could be viewed as opportunistic pathogens in genetically susceptible hosts with innate killing, mucosal barrier or immunoregulatory defects, with no disease induced in normal hosts. Identifying and then eliminating these strains, blocking expression of their virulence factors or altering their metabolism and identifying host susceptibility factors could be essential keys to treating IBD. Likewise, identifying changes in microbiota composition, gene expression and metabolic profiles in different IBD patient subsets using rapidly evolving molecular tools will provide important new insights into the pathogenesis and novel treatment of IBD using the example of F. prausnitzii [49 ] . Meanwhile, using probiotics and prebiotics to enhance concentrations of beneficial species remains promising, although clinical trials lack statistical power due to small numbers. Treatments need to be individualized on the basis of compositional alterations in patient subsets. Understanding bacterial and host mutalistic interactions will determine success in this area.
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